For Immediate Release
Chicago, IL – September 15, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include TOTAL (TOT), Oracle (NYSE:ORCL) (ORCL) and Gilead Sciences (NASDAQ:GILD) (GILD) .
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
Here are highlights from Wednesday’s Analyst Blog:
New Oracle (ORCL), Gilead (GILD) and TOTAL (TOT) Research Reports
Today's Research Daily features new research reports on 16 major stocks, including TOTAL (TOT), Oracle (ORCL) and Gilead Sciences (GILD). Please note that these 16 reports have been handpicked from the more than 80 research reports issued by our analyst team today. You can see the complete list of today's research reports here >>>
Shares of French oil major TOTAL have come down in recent days, as have other oil stocks, in response to weakness in the commodity on IEA’s dismal global oil demand forecasts. But this Zacks Rank # 2 (Buy) stock is still up nicely on the year, with the company making a concerted effort to increase its footprint in the U.S. The recent deal to acquire Chesapeake's stake in the prolific Barnett Shale basin is a step in that direction. The Zacks analyst likes the company’s efforts to that end and explains them in detail in the research report published today. (You can read the full research report on TOTAL here>>)
Oracle shares have been strong performers this year, up more than 10% year-to-date, on the back of favorable momentum in its cloud-based products, SaaS and PaaS that are expected to be key growth drivers in its quarterly report coming out after the close on Thursday (September 15th). The Zacks analyst likes the company’s Big Data and digitalization initiatives, which is expected to boost its database management system growth. However, Oracle’s business transition from licensing to cloud is a drag on the financials at present. It lost a JAVA APIs lawsuit against Alphabet’s Google (NASDAQ:GOOGL) and another Itanium software lawsuit against HPE, which also remains an overhang on the stock. (You can read the full research report on Oracle here>>)
Gilead Sciences shares have been laggards this year, losing nearly 22.9% year-to-date, as the HCV franchise continues to witness slowdown in the U.S. and Europe due to lower sales of Harvoni. Gilead lowered its 2016 product sales outlook, reflecting the current trends in the payer and patient flow dynamics for HCV among other factors. Despite these concerns, the Zacks analyst likes the company’s well performing HIV franchise, which is expected to get a further boost from its newly launched HIV treatments like Genvoya. The company also has a robust late-stage pipeline that bodes well for its long-term growth. (You can read the full research report on Gilead Sciences here>>)
Other noteworthy reports today include JPMorgan Chase (NYSE:JPM), which has been downgraded to Zacks Rank # 4 (Sell), and Equinix (NASDAQ:EQIX), which moves up to Zacks Rank # 2 (Buy).
You can find all of today's stock research reports here>>
Today's Long-Term Buys & Sells
Today you can gain access to the best long-term trades unearthed by Zacks Research. These moves have double and triple-digit profit potential and are rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>
Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
Follow us on Twitter: https://twitter.com/zacksresearch
Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
TOTAL FINA SA (TOT): Free Stock Analysis Report
ORACLE CORP (ORCL): Free Stock Analysis Report
GILEAD SCIENCES (GILD): Free Stock Analysis Report
Original post